News and Announcements

GSK hoping to expand Arexvy usage in Japan

By Benjamin Chiou

Date: Friday 20 Jun 2025

(Sharecast News) - Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult population.
Arexvy is now being considered for those aged 18 to 49 who are at increased risk of severe RSV disease, following positive Phase IIIb data showing immune...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page